Fig. 4: COL11A1-CAR T cells have potent antitumor activity in vivo.
From: Discovery of immunotherapy targets for pediatric solid and brain tumors by exon-level expression
A Schematic of LM7 OS animal experiment. Day 0: i.p. injection of 1 × 106 LM7.GFP.ffluc cells; Day 7: i.v. injection of 3 × 106 NT or CAR T-cells (n = 10) mice per group; 2 different biologically independent T-cell donors (5 mice per donor); Tu: tumor cells; intraperitoneal (i.p.), subcutaneous (s.c.), intravenous (i.v.) injection. B Representative bioluminescence images until day 55 post tumor cell injection (all life mice are shown for each group (n = 10 mice per group)). C Quantitative bioluminescence data (Radiance: photons/sec/cm2/sr) (n = 10 mice per group). D Kaplan-Meier survival curve, log-rank (Mantel-Cox) test; ****p < 0.0001 (n = 10 mice per group). E Weight (g) of mice (n = 10 mice per group). (F) Schematic of A673 EWS animal experiment. Day 0: s.c. injection of 1 × 106 A673 cells; Day 7: i.v. injection of 3 × 106 NT or CAR T-cells (n = 5 mice per group). (G) Tumors measured weekly by caliper measurements (n = 5 mice per group). (H) Kaplan-Meier survival curve, log-rank (Mantel-Cox) test, *p = 0.0112 (n = 5 mice per group). I Weight (g) of mice.
